Respimat® Inhaler

The Respimat® inhaler is a soft-mist inhaler available as SPIOLTO® Respimat® (tiotropium/olodaterol) for adult patients with COPD and SPIRIVA® Respimat® (tiotropium) for patients with COPD and Severe Asthma.1–4

SPIOLTO® Respimat® and SPIRIVA®Respimat® are indicated as maintenance bronchodilator treatments to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).1,2

SPIRIVA® Respimat® is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.2

The Respimat® inhaler provides a consistent dose to the lungs, independent of inspiratory ability.*5,6

*These studies simulated the upper airways (in vitro) and the lower airways (in silico) of patients with moderate and very severe COPD.5,6

Quick links

Respimat® for patients with COPD and Severe Asthma

Find out how Respimat® can support your patients with COPD and Severe Asthma.

Read more
Close up of 3 COPD patients & their current medications
Webpage

How would you treat breathless COPD patients?

see morePC-GB-105543 May 2022
 

How to use the Respimat® inhaler

Familiarise yourself with our Respimat® device by watching our demonstration videos or by downloading our how-to-use summary.

 
 
 

Patient Respiratory Resources

Materials to help provide ongoing support to your patients with COPD

View our SPIOLTO® Respimat® (tiotropium/olodaterol) and SPIRIVA® Respimat® (tiotropium) resources that you can download and share electronically with your patients.

 
References

1.

SPIOLTO® Respimat® Summary of Product Characteristics.

2.

SPIRIVA® Respimat® Summary of Product Characteristics.

3.

Hochrainer D et al. J Aerosol Med 2005;18:273–282.

4.

Dalby R et al. Int J Pharm 2004;283:1–9.

5.

Ciciliani AM et al. COPD. 2021;18(1):91–100.

6.

Ciciliani AM et al. Int J Chron Obstruct Pulmon Dis 2017;12:1565−1577.

Some of the content on this website was created before the COVID-19 pandemic. Please refer to national and local guidelines for the latest recommendations on COVID-19 and consider their impact on the materials included on this website. These assets are intended to be viewed online.

PC-GB-103264 V3

April 2023

Reporting adverse events

Adverse events should be reported. Reporting form and information can be found atwww.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.